Navigation Links
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to Reach USD 766 Mln by 2019, Says GBI Research in Its Report Available at MarketPublishers.com
Date:1/6/2014

London, UK (PRWEB) January 06, 2014

Currently, esophageal and gastric cancers are the two major types of cancer associated with the gastrointestinal tract. These kinds of cancer are usually diagnosed only at advanced and incurable stages given a late onset of symptoms. However, the diseases also demonstrate low survival rates even in the early stages. At present, the key options used to treat esophageal and gastric cancers include surgery and chemotherapy. One monoclonal antibody (mAb), namely Herceptin, is currently marketed for the use in suitable patients with advanced gastro-esophageal or gastric junction cancer.

Nowadays, the late-stage esophageal and gastric cancers pipelines include numerous promising mAbs candidates that are likely to enter the marketplace during 2014-2019. Actual market environment is regarded as rather favourable for new mAbs, with weak impact from biosimilar exposure along with high pricing patterns. The value of the overall market for mAbs in gastric and esophageal cancers is expected to touch the USD 766 million mark by 2019.

In-demand research study "Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth" worked out by GBI Research has been recently published by Market Publishers Ltd.

Report Details:

Title: Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Published: December, 2013
Pages: 106
Price:    US$ 3,500.00
http://marketpublishers.com/report/diagnostics-diseases/cancer/monoclonal-antibodies-market-in-gastric-n-esophageal-cancers-to-2019.html

The report is a comprehensive guide to the market for mAbs in gastric and esophageal cancers. It contains detailed diseases’ profiles, including coverage of symptoms, etiology, epidemiology, pathophysiology, risk factors, diagnosis, treatment options, etc.; highlights the historical and current development of the gastric and esophageal cancers overall pipelines, reviews the major pipeline products available, as well as uncovers vital data on the drugs that are expected to enter the market in the offing. The report traces the recent deals and strategic consolidations in the examined field, offers a profound analysis of pipeline drug clinical trials, draws up a forecast scenario of the market performance up to 2019, and also scrutinizes the impact of the expiry of key current patents on the current drugs, the emergence of new drugs, and certain changes in disease epidemiology across the main geographical markets – the US, Japan Canada, the UK, Germany, Italy, France, and Spain.

Report Features & Benefits:

  •     Determine and understand the unmet needs in the treatment of gastric and esophageal cancers.
  •     Evaluate the role of Herceptin and pinpoint the promising opportunities for other mAbs to enter the market.
  •     Get an idea of the pipeline scope and understand the prominent molecule types and mechanisms of action.
  •     Observe the trends prevailing in the field and at certain development phases.
  •     Assess the risks of the current and future programs for mAbs in gastric and esophageal cancers with the help of the clinical trial failure rate analysis.
  •     Trace the shift in clinical trial endpoints, and thus use the acquired knowledge to influence any future development programmes.
  •     Assess the key drivers and barriers of the market growth.
  •     Get an idea of how the market landscape is set to change through to 2019.

More insightful research reports by GBI Research can be found at http://marketpublishers.com/members/gbiresearch/info.html

Read the full story at http://www.prweb.com/releases/2014/01/prweb11464191.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
2. Monoclonal antibody appears effective and safe in asthma Phase IIa trial
3. Monoclonal Antibodies Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
4. Monoclonal Antibodies Market Dealmaking in Biopharma Industry Analyzed in New Research Report at ReportsnReports.com
5. Monoclonal antibody effective against norovirus
6. Global & China Monoclonal Antibody Market Analysis and 2017 Forecasts in New Research Report at RnRMarketResearch.com
7. Maine Biotechnology Services-USDA-ARS Partnership Provides Monoclonal Antibodies to Aid in the Containment of Rift Valley Fever Virus
8. Global and China Monoclonal Antibody Industry Report 2013 Analysis and 2017 Market Focus by Researchmoz.us
9. Antibodies reverse type 1 diabetes in new immunotherapy study
10. Antibodies from rabbits reduce risks associated with
11. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better ... ultimately do significant harm to people with all chronic conditions, including mental illnesses, ... leaves in place the Affordable Care Act (ACA) requirement that insurers cover pre-existing ...
(Date:6/23/2017)... , ... June 24, 2017 , ... Studies show evidence ... reduce the risk of visual loss in these patients. , But how often do ... or smoking cessation to patients at risk of or with early symptoms of AMD? ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection ... denied entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger ... six years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class ...
(Date:6/23/2017)... ... ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach to ... technique that he calls the AuraLyft Facelift. The AuraLyft does more than ... expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach stems ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the development of ... R&D and Head of Virology Kristin Bedard has been invited ... and Beyond meeting sponsored by Life Science Washington.  This ... AM PDT at the Agora Conference Center in ... be joined by other leaders in infectious disease research and ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 /PRNewswire/ ... diabetes. In a further effort to help spread lessons ... this condition, the International Diabetes Federation (IDF) and Eli ... come together for the second phase of the Bringing ... (BRIDGES 2), reaffirming their commitment to helping people with ...
Breaking Medicine Technology: